Open an account

GridAI Technologies

FWBI · NASDAQ

$4.63+$0.24 (+5.47%)TodayMarket closed ·
Prev close $4.39

FWBI analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated May 15, 2024

Bull case

First Wave BioPharma is well positioned for success in the biopharmaceutical industry with its compelling clinical-stage pipeline, including its proprietary technologies of niclosamide and adrulipase. The acquisition of ImmunogenX and their almost Phase 3-ready latiglutenase provides a promising opportunity for FWBI to tap into the celiac disease market, with positive results seen in the seropositive patient subset taking the highest dose of 900mg daily. With a focus on securing financing and completing the pivotal program and regulatory requirements, FWBI has the potential to secure approval for latiglutenase and bring value to patients and investors alike.

Bear case

First Wave BioPharma is at risk of multiple setbacks and challenges in the development and commercialization of their products, including potential failure to show statistical significance in clinical trials, failure to gain regulatory approval, and a competitive marketplace. Additionally, the impact of COVID-19 on enrollment and financing risks could also impede the achievement of First Wave BioPharma's target price. With a difficult endpoint to achieve and a substantial market opportunity reliant on still-unapproved therapeutics, there is a high level of uncertainty and risk for investors in this stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.